<DOC>
	<DOCNO>NCT02874885</DOCNO>
	<brief_summary>Objectives : - To establish rate circulate tumor cell ( CTC ) positivity patient locally-advanced rectal cancer ( LARC ) , relative stage ; - To assess change detect CTCs associate neoadjuvant therapy patient LARC ; - To correlate CTC count neoadjuvant treatment response indicator disease risk .</brief_summary>
	<brief_title>Circulating Tumor Cells Patients With Rectal Cancer</brief_title>
	<detailed_description>Healthy Participants : If participant diagnose colorectal cancer , blood ( 2 tablespoon ) draw 1 time . This blood use control ( normal ) look difference cell blood patient colorectal cancer . Once participant 's blood collect , participation study . This study research purpose . Test result place participant 's medical record , inform outcome test result . This investigational study . Up 520 participant enrol study . All enrol MD Anderson . Rectal Cancer Participants : If participant agrees take part study , blood drawn test CTCs . Rectal Cancer Participants : If patient participant diagnose rectal ( rectosigmoid ) cancer , blood ( 2 tablespoon ) may draw 1 time participant start treatment . Additional Blood Draws Rectal Cancer Patients ONLY : Blood ( 2 tablespoon ) may also draw CTC test follow time point : - Just tumor surgery - 1-8 week participant 's surgery , begin chemotherapy - 1-12 week last dose chemotherapy - 1 year participant 's surgery ( +/- 8 week ) OR 1 year completion treatment participant surgery - 2 year participant 's surgery ( +/- 8 week ) OR 2 year completion treatment participant surgery - If disease get bad treatment OR If disease come back within 6 year treatment OR end 6 year follow-up If problem participant 's sample testing AND still one timepoints list , participant may ask provide extra blood ( 2 tablespoon ) complete study test . Whenever possible , blood draw do part routine blood draw , participant may need come clinic . If participant chooses receive follow-up care away MD Anderson , ask allow study staff contact phone email . Participant ask status disease give instruction provide blood sample time point . This investigational study . Up 520 participant enrol study . All take part MD Anderson regional care center .</detailed_description>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Neoplastic Cells , Circulating</mesh_term>
	<criteria>1 . Adult participant ( Age &gt; /= 18 year old ) 2 . Meets one follow definition : 1 . Healthy Subject : No known diagnosis colorectal cancer ( CRC ) type cancer last 10 year . ( basal cell skin cancer allow ) Subjects ask cancer history verbal confirmation require . . 2 . Any patient diagnosis rectal ( rectosigmoid ) cancer , include : Patients primary disease without neoadjuvant therapy ; OR Patients recurrent disease without neoadjuvant therapy ; OR Patients metastatic disease without prior treatment 3 . No known current diagnosis cancer ; prior diagnosis cancer , he/she free cancer &gt; /= 6 year active treatment . 4 . Adequate mental language capacity provide consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Locally-advanced rectal cancer</keyword>
	<keyword>LARC</keyword>
	<keyword>Colorectal cancer</keyword>
	<keyword>CRC</keyword>
	<keyword>Rectosigmoid cancer</keyword>
	<keyword>No known diagnosis colorectal cancer</keyword>
	<keyword>Blood draw</keyword>
	<keyword>Blood sample</keyword>
	<keyword>Circulating tumor cell ( CTC )</keyword>
	<keyword>CTC</keyword>
</DOC>